Precision Value & Health recently surveyed 25 key decision makers at leading health plans and delivery networks regarding gene therapy—including who should be treated and when. STAT shares the intriguing results in this article by Jeremy Shafer, Senior VP of Access Experience, Precision for Value. Hint: cost isn’t the only answer.

Read the article